Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1992 Feb;33(2):190–192. doi: 10.1111/j.1365-2125.1992.tb04024.x

Extrahepatic metabolism of zidovudine.

J L Howe 1, D J Back 1, J Colbert 1
PMCID: PMC1381307  PMID: 1550699

Abstract

The metabolism of zidovudine (3'-azido-3'-deoxythymidine; AZT) has been studied in human renal, gut and hepatic microsomes. Metabolism of AZT to the ether glucuronide (3'azido-3'-deoxy-5'-beta-D-glucopyranosyl thymidine; GAZT) occurred in the kidney with Km and Vmax values of 1.50 +/- 0.49 mM and 14.5 +/- 2.6 nmol h-1 mg-1 respectively (mean +/- s.d.; n = 3 batches of microsomes from a single kidney). Comparative values obtained in liver were 2.19 +/- 0.6 mM and 43.0 +/- 9.5 nmol h-1 mg-1, respectively. Morphine caused inhibition of AZT conjugation in kidney microsomes. Metabolism of AZT by the kidney could contribute significantly to the overall elimination of AZT. In contrast to the kidney findings, AZT was not metabolised to GAZT by either non-activated (Brij-58) or activated gut microsomes.

Full text

PDF
190

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Cload P. A. A review of the pharmacokinetics of zidovudine in man. J Infect. 1989 Jan;18 (Suppl 1):15–21. doi: 10.1016/s0163-4453(89)80076-3. [DOI] [PubMed] [Google Scholar]
  2. Cretton E. M., Waterhous D. V., Bevan R., Sommadossi J. P. Glucuronidation of 3'-azido-3'-deoxythymidine by rat and human liver microsomes. Drug Metab Dispos. 1990 May-Jun;18(3):369–372. [PubMed] [Google Scholar]
  3. Good S. S., Koble C. S., Crouch R., Johnson R. L., Rideout J. L., de Miranda P. Isolation and characterization of an ether glucuronide of zidovudine, a major metabolite in monkeys and humans. Drug Metab Dispos. 1990 May-Jun;18(3):321–326. [PubMed] [Google Scholar]
  4. Klecker R. W., Jr, Collins J. M., Yarchoan R., Thomas R., Jenkins J. F., Broder S., Myers C. E. Plasma and cerebrospinal fluid pharmacokinetics of 3'-azido-3'-deoxythymidine: a novel pyrimidine analog with potential application for the treatment of patients with AIDS and related diseases. Clin Pharmacol Ther. 1987 Apr;41(4):407–412. doi: 10.1038/clpt.1987.49. [DOI] [PubMed] [Google Scholar]
  5. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  6. Lopez-Anaya A., Unadkat J. D., Schumann L. A., Smith A. L. Pharmacokinetics of zidovudine (azidothymidine). II. Development of metabolic and renal clearance pathways in the neonate. J Acquir Immune Defic Syndr. 1990;3(11):1052–1058. [PubMed] [Google Scholar]
  7. Mazoit J. X., Sandouk P., Scherrmann J. M., Roche A. Extrahepatic metabolism of morphine occurs in humans. Clin Pharmacol Ther. 1990 Dec;48(6):613–618. doi: 10.1038/clpt.1990.203. [DOI] [PubMed] [Google Scholar]
  8. Miners J. O., Lillywhite K. J. Assessment of the drug inhibitor specificity of the human liver 4-methylumbelliferone UDP-glucuronosyltransferase activity. Biochem Pharmacol. 1991 Mar 1;41(5):838–841. doi: 10.1016/0006-2952(91)90090-r. [DOI] [PubMed] [Google Scholar]
  9. Peters W. H., Jansen P. L. Immunocharacterization of UDP-glucuronyltransferase isoenzymes in human liver, intestine and kidney. Biochem Pharmacol. 1988 Feb 1;37(3):564–567. doi: 10.1016/0006-2952(88)90234-1. [DOI] [PubMed] [Google Scholar]
  10. Peters W. H., Kock L., Nagengast F. M., Kremers P. G. Biotransformation enzymes in human intestine: critical low levels in the colon? Gut. 1991 Apr;32(4):408–412. doi: 10.1136/gut.32.4.408. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Resetar A., Minick D., Spector T. Glucuronidation of 3'-azido-3'-deoxythymidine catalyzed by human liver UDP-glucuronosyltransferase. Significance of nucleoside hydrophobicity and inhibition by xenobiotics. Biochem Pharmacol. 1991 Jul 15;42(3):559–568. doi: 10.1016/0006-2952(91)90319-z. [DOI] [PubMed] [Google Scholar]
  12. Resetar A., Spector T. Glucuronidation of 3'-azido-3'-deoxythymidine: human and rat enzyme specificity. Biochem Pharmacol. 1989 May 1;38(9):1389–1393. doi: 10.1016/0006-2952(89)90177-9. [DOI] [PubMed] [Google Scholar]
  13. Sim S. M., Back D. J., Breckenridge A. M. The effect of various drugs on the glucuronidation of zidovudine (azidothymidine; AZT) by human liver microsomes. Br J Clin Pharmacol. 1991 Jul;32(1):17–21. doi: 10.1111/j.1365-2125.1991.tb05607.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Singlas E., Pioger J. C., Taburet A. M., Colin J. N., Fillastre J. P. Zidovudine disposition in patients with severe renal impairment: influence of hemodialysis. Clin Pharmacol Ther. 1989 Aug;46(2):190–197. doi: 10.1038/clpt.1989.125. [DOI] [PubMed] [Google Scholar]
  15. Yue Q., von Bahr C., Odar-Cederlöf I., Säwe J. Glucuronidation of codeine and morphine in human liver and kidney microsomes: effect of inhibitors. Pharmacol Toxicol. 1990 Mar;66(3):221–226. doi: 10.1111/j.1600-0773.1990.tb00737.x. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES